nodes	percent_of_prediction	percent_of_DWPC	metapath
Tobramycin—Cough—Tiotropium—chronic obstructive pulmonary disease	0.00204	0.00204	CcSEcCtD
Tobramycin—Pharyngitis—Salbutamol—chronic obstructive pulmonary disease	0.00203	0.00203	CcSEcCtD
Tobramycin—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	0.00202	0.00202	CcSEcCtD
Tobramycin—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.00202	0.00202	CcSEcCtD
Tobramycin—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.00201	0.00201	CcSEcCtD
Tobramycin—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.002	0.002	CcSEcCtD
Tobramycin—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.002	0.002	CcSEcCtD
Tobramycin—Chest pain—Tiotropium—chronic obstructive pulmonary disease	0.00199	0.00199	CcSEcCtD
Tobramycin—Myalgia—Tiotropium—chronic obstructive pulmonary disease	0.00199	0.00199	CcSEcCtD
Tobramycin—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.00198	0.00198	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.00198	0.00198	CcSEcCtD
Tobramycin—Delirium—Prednisone—chronic obstructive pulmonary disease	0.00197	0.00197	CcSEcCtD
Tobramycin—Thrombophlebitis—Prednisolone—chronic obstructive pulmonary disease	0.00196	0.00196	CcSEcCtD
Tobramycin—Immune system disorder—Formoterol—chronic obstructive pulmonary disease	0.00196	0.00196	CcSEcCtD
Tobramycin—Immune system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00196	0.00196	CcSEcCtD
Tobramycin—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00195	0.00195	CcSEcCtD
Tobramycin—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00195	0.00195	CcSEcCtD
Tobramycin—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.00193	0.00193	CcSEcCtD
Tobramycin—Anorexia—Aminophylline—chronic obstructive pulmonary disease	0.00193	0.00193	CcSEcCtD
Tobramycin—Immune system disorder—Montelukast—chronic obstructive pulmonary disease	0.00192	0.00192	CcSEcCtD
Tobramycin—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00191	0.00191	CcSEcCtD
Tobramycin—Rash—Roflumilast—chronic obstructive pulmonary disease	0.00191	0.00191	CcSEcCtD
Tobramycin—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.00191	0.00191	CcSEcCtD
Tobramycin—Tinnitus—Salbutamol—chronic obstructive pulmonary disease	0.00191	0.00191	CcSEcCtD
Tobramycin—Headache—Roflumilast—chronic obstructive pulmonary disease	0.0019	0.0019	CcSEcCtD
Tobramycin—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00187	0.00187	CcSEcCtD
Tobramycin—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.00186	0.00186	CcSEcCtD
Tobramycin—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.00185	0.00185	CcSEcCtD
Tobramycin—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00185	0.00185	CcSEcCtD
Tobramycin—Dysgeusia—Arformoterol—chronic obstructive pulmonary disease	0.00185	0.00185	CcSEcCtD
Tobramycin—Dysgeusia—Formoterol—chronic obstructive pulmonary disease	0.00185	0.00185	CcSEcCtD
Tobramycin—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00184	0.00184	CcSEcCtD
Tobramycin—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.00182	0.00182	CcSEcCtD
Tobramycin—Back pain—Formoterol—chronic obstructive pulmonary disease	0.00182	0.00182	CcSEcCtD
Tobramycin—Leukocytosis—Prednisone—chronic obstructive pulmonary disease	0.00181	0.00181	CcSEcCtD
Tobramycin—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.0018	0.0018	CcSEcCtD
Tobramycin—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.00176	0.00176	CcSEcCtD
Tobramycin—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.00175	0.00175	CcSEcCtD
Tobramycin—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.00175	0.00175	CcSEcCtD
Tobramycin—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.00174	0.00174	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.00174	0.00174	CcSEcCtD
Tobramycin—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.00172	0.00172	CcSEcCtD
Tobramycin—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.00172	0.00172	CcSEcCtD
Tobramycin—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.00172	0.00172	CcSEcCtD
Tobramycin—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.00171	0.00171	CcSEcCtD
Tobramycin—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.0017	0.0017	CcSEcCtD
Tobramycin—Malaise—Formoterol—chronic obstructive pulmonary disease	0.0017	0.0017	CcSEcCtD
Tobramycin—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.00169	0.00169	CcSEcCtD
Tobramycin—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.00165	0.00165	CcSEcCtD
Tobramycin—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.00165	0.00165	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00165	0.00165	CcSEcCtD
Tobramycin—Cough—Formoterol—chronic obstructive pulmonary disease	0.00165	0.00165	CcSEcCtD
Tobramycin—Cough—Arformoterol—chronic obstructive pulmonary disease	0.00165	0.00165	CcSEcCtD
Tobramycin—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.00163	0.00163	CcSEcCtD
Tobramycin—Cough—Montelukast—chronic obstructive pulmonary disease	0.00161	0.00161	CcSEcCtD
Tobramycin—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.00161	0.00161	CcSEcCtD
Tobramycin—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.00161	0.00161	CcSEcCtD
Tobramycin—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.00161	0.00161	CcSEcCtD
Tobramycin—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.00161	0.00161	CcSEcCtD
Tobramycin—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.00161	0.00161	CcSEcCtD
Tobramycin—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.00161	0.00161	CcSEcCtD
Tobramycin—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.0016	0.0016	CcSEcCtD
Tobramycin—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.0016	0.0016	CcSEcCtD
Tobramycin—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.0016	0.0016	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.00159	0.00159	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.00159	0.00159	CcSEcCtD
Tobramycin—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00159	0.00159	CcSEcCtD
Tobramycin—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.00159	0.00159	CcSEcCtD
Tobramycin—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.00157	0.00157	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.00156	0.00156	CcSEcCtD
Tobramycin—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00156	0.00156	CcSEcCtD
Tobramycin—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.00155	0.00155	CcSEcCtD
Tobramycin—Cough—Salbutamol—chronic obstructive pulmonary disease	0.00155	0.00155	CcSEcCtD
Tobramycin—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.00154	0.00154	CcSEcCtD
Tobramycin—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.00154	0.00154	CcSEcCtD
Tobramycin—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.00152	0.00152	CcSEcCtD
Tobramycin—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.00152	0.00152	CcSEcCtD
Tobramycin—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.00151	0.00151	CcSEcCtD
Tobramycin—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00151	0.00151	CcSEcCtD
Tobramycin—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00151	0.00151	CcSEcCtD
Tobramycin—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00151	0.00151	CcSEcCtD
Tobramycin—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.00151	0.00151	CcSEcCtD
Tobramycin—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.0015	0.0015	CcSEcCtD
Tobramycin—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.0015	0.0015	CcSEcCtD
Tobramycin—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00149	0.00149	CcSEcCtD
Tobramycin—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00149	0.00149	CcSEcCtD
Tobramycin—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.00149	0.00149	CcSEcCtD
Tobramycin—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.00148	0.00148	CcSEcCtD
Tobramycin—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.00148	0.00148	CcSEcCtD
Tobramycin—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.00146	0.00146	CcSEcCtD
Tobramycin—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.00145	0.00145	CcSEcCtD
Tobramycin—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.00143	0.00143	CcSEcCtD
Tobramycin—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00142	0.00142	CcSEcCtD
Tobramycin—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	0.00142	0.00142	CcSEcCtD
Tobramycin—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00141	0.00141	CcSEcCtD
Tobramycin—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.0014	0.0014	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.0014	0.0014	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.0014	0.0014	CcSEcCtD
Tobramycin—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.00138	0.00138	CcSEcCtD
Tobramycin—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00138	0.00138	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.00137	0.00137	CcSEcCtD
Tobramycin—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.00137	0.00137	CcSEcCtD
Tobramycin—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.00137	0.00137	CcSEcCtD
Tobramycin—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.00135	0.00135	CcSEcCtD
Tobramycin—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.00135	0.00135	CcSEcCtD
Tobramycin—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.00134	0.00134	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00133	0.00133	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00133	0.00133	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00132	0.00132	CcSEcCtD
Tobramycin—Pain—Arformoterol—chronic obstructive pulmonary disease	0.00132	0.00132	CcSEcCtD
Tobramycin—Pain—Formoterol—chronic obstructive pulmonary disease	0.00132	0.00132	CcSEcCtD
Tobramycin—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.0013	0.0013	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.0013	0.0013	CcSEcCtD
Tobramycin—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.0013	0.0013	CcSEcCtD
Tobramycin—Pain—Montelukast—chronic obstructive pulmonary disease	0.00129	0.00129	CcSEcCtD
Tobramycin—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00129	0.00129	CcSEcCtD
Tobramycin—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.00128	0.00128	CcSEcCtD
Tobramycin—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00127	0.00127	CcSEcCtD
Tobramycin—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00127	0.00127	CcSEcCtD
Tobramycin—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.00127	0.00127	CcSEcCtD
Tobramycin—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.00127	0.00127	CcSEcCtD
Tobramycin—Headache—Aminophylline—chronic obstructive pulmonary disease	0.00127	0.00127	CcSEcCtD
Tobramycin—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.00126	0.00126	CcSEcCtD
Tobramycin—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.00126	0.00126	CcSEcCtD
Tobramycin—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.00126	0.00126	CcSEcCtD
Tobramycin—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.00126	0.00126	CcSEcCtD
Tobramycin—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.00126	0.00126	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00125	0.00125	CcSEcCtD
Tobramycin—Pain—Salbutamol—chronic obstructive pulmonary disease	0.00124	0.00124	CcSEcCtD
Tobramycin—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00123	0.00123	CcSEcCtD
Tobramycin—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.00122	0.00122	CcSEcCtD
Tobramycin—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.00122	0.00122	CcSEcCtD
Tobramycin—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.00122	0.00122	CcSEcCtD
Tobramycin—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.00122	0.00122	CcSEcCtD
Tobramycin—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.00122	0.00122	CcSEcCtD
Tobramycin—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.00122	0.00122	CcSEcCtD
Tobramycin—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00121	0.00121	CcSEcCtD
Tobramycin—Rash—Tiotropium—chronic obstructive pulmonary disease	0.0012	0.0012	CcSEcCtD
Tobramycin—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.0012	0.0012	CcSEcCtD
Tobramycin—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.0012	0.0012	CcSEcCtD
Tobramycin—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.0012	0.0012	CcSEcCtD
Tobramycin—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.0012	0.0012	CcSEcCtD
Tobramycin—Headache—Tiotropium—chronic obstructive pulmonary disease	0.00119	0.00119	CcSEcCtD
Tobramycin—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.00119	0.00119	CcSEcCtD
Tobramycin—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.00119	0.00119	CcSEcCtD
Tobramycin—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.00119	0.00119	CcSEcCtD
Tobramycin—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.00115	0.00115	CcSEcCtD
Tobramycin—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00115	0.00115	CcSEcCtD
Tobramycin—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.00115	0.00115	CcSEcCtD
Tobramycin—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00113	0.00113	CcSEcCtD
Tobramycin—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00113	0.00113	CcSEcCtD
Tobramycin—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00113	0.00113	CcSEcCtD
Tobramycin—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.00113	0.00113	CcSEcCtD
Tobramycin—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.00113	0.00113	CcSEcCtD
Tobramycin—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.00112	0.00112	CcSEcCtD
Tobramycin—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.00111	0.00111	CcSEcCtD
Tobramycin—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.0011	0.0011	CcSEcCtD
Tobramycin—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.0011	0.0011	CcSEcCtD
Tobramycin—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.00109	0.00109	CcSEcCtD
Tobramycin—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.00109	0.00109	CcSEcCtD
Tobramycin—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.00109	0.00109	CcSEcCtD
Tobramycin—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.00108	0.00108	CcSEcCtD
Tobramycin—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.00107	0.00107	CcSEcCtD
Tobramycin—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.00107	0.00107	CcSEcCtD
Tobramycin—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.00105	0.00105	CcSEcCtD
Tobramycin—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.00105	0.00105	CcSEcCtD
Tobramycin—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.00104	0.00104	CcSEcCtD
Tobramycin—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.00103	0.00103	CcSEcCtD
Tobramycin—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.00103	0.00103	CcSEcCtD
Tobramycin—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.00102	0.00102	CcSEcCtD
Tobramycin—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.00102	0.00102	CcSEcCtD
Tobramycin—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.00102	0.00102	CcSEcCtD
Tobramycin—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000997	0.000997	CcSEcCtD
Tobramycin—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000994	0.000994	CcSEcCtD
Tobramycin—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000978	0.000978	CcSEcCtD
Tobramycin—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000978	0.000978	CcSEcCtD
Tobramycin—Rash—Arformoterol—chronic obstructive pulmonary disease	0.00097	0.00097	CcSEcCtD
Tobramycin—Rash—Formoterol—chronic obstructive pulmonary disease	0.00097	0.00097	CcSEcCtD
Tobramycin—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000969	0.000969	CcSEcCtD
Tobramycin—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000969	0.000969	CcSEcCtD
Tobramycin—Headache—Formoterol—chronic obstructive pulmonary disease	0.000964	0.000964	CcSEcCtD
Tobramycin—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000964	0.000964	CcSEcCtD
Tobramycin—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000963	0.000963	CcSEcCtD
Tobramycin—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000962	0.000962	CcSEcCtD
Tobramycin—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000961	0.000961	CcSEcCtD
Tobramycin—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000958	0.000958	CcSEcCtD
Tobramycin—Rash—Montelukast—chronic obstructive pulmonary disease	0.00095	0.00095	CcSEcCtD
Tobramycin—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000949	0.000949	CcSEcCtD
Tobramycin—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000947	0.000947	CcSEcCtD
Tobramycin—Headache—Montelukast—chronic obstructive pulmonary disease	0.000944	0.000944	CcSEcCtD
Tobramycin—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000933	0.000933	CcSEcCtD
Tobramycin—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000931	0.000931	CcSEcCtD
Tobramycin—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000924	0.000924	CcSEcCtD
Tobramycin—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000921	0.000921	CcSEcCtD
Tobramycin—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000917	0.000917	CcSEcCtD
Tobramycin—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000916	0.000916	CcSEcCtD
Tobramycin—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000915	0.000915	CcSEcCtD
Tobramycin—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000914	0.000914	CcSEcCtD
Tobramycin—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000914	0.000914	CcSEcCtD
Tobramycin—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00091	0.00091	CcSEcCtD
Tobramycin—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000895	0.000895	CcSEcCtD
Tobramycin—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000863	0.000863	CcSEcCtD
Tobramycin—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000859	0.000859	CcSEcCtD
Tobramycin—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000838	0.000838	CcSEcCtD
Tobramycin—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000833	0.000833	CcSEcCtD
Tobramycin—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000797	0.000797	CcSEcCtD
Tobramycin—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000773	0.000773	CcSEcCtD
Tobramycin—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.00077	0.00077	CcSEcCtD
Tobramycin—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000748	0.000748	CcSEcCtD
Tobramycin—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000742	0.000742	CcSEcCtD
Tobramycin—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000713	0.000713	CcSEcCtD
Tobramycin—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000699	0.000699	CcSEcCtD
Tobramycin—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000688	0.000688	CcSEcCtD
Tobramycin—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000687	0.000687	CcSEcCtD
Tobramycin—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000686	0.000686	CcSEcCtD
Tobramycin—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000678	0.000678	CcSEcCtD
Tobramycin—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000669	0.000669	CcSEcCtD
Tobramycin—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000667	0.000667	CcSEcCtD
Tobramycin—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000662	0.000662	CcSEcCtD
Tobramycin—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000632	0.000632	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000627	0.000627	CcSEcCtD
Tobramycin—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000624	0.000624	CcSEcCtD
Tobramycin—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000614	0.000614	CcSEcCtD
Tobramycin—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000606	0.000606	CcSEcCtD
Tobramycin—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000594	0.000594	CcSEcCtD
Tobramycin—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000588	0.000588	CcSEcCtD
Tobramycin—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000577	0.000577	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000552	0.000552	CcSEcCtD
Tobramycin—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000551	0.000551	CcSEcCtD
Tobramycin—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000544	0.000544	CcSEcCtD
Tobramycin—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000526	0.000526	CcSEcCtD
Tobramycin—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000525	0.000525	CcSEcCtD
Tobramycin—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000525	0.000525	CcSEcCtD
Tobramycin—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000522	0.000522	CcSEcCtD
Tobramycin—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000499	0.000499	CcSEcCtD
Tobramycin—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000495	0.000495	CcSEcCtD
Tobramycin—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000495	0.000495	CcSEcCtD
Tobramycin—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000481	0.000481	CcSEcCtD
Tobramycin—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000479	0.000479	CcSEcCtD
Tobramycin—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000479	0.000479	CcSEcCtD
Tobramycin—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000446	0.000446	CcSEcCtD
Tobramycin—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000434	0.000434	CcSEcCtD
Tobramycin—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000428	0.000428	CcSEcCtD
Tobramycin—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000414	0.000414	CcSEcCtD
Tobramycin—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.0004	0.0004	CcSEcCtD
Tobramycin—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000385	0.000385	CcSEcCtD
Tobramycin—Rash—Prednisone—chronic obstructive pulmonary disease	0.000382	0.000382	CcSEcCtD
Tobramycin—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000381	0.000381	CcSEcCtD
Tobramycin—Headache—Prednisone—chronic obstructive pulmonary disease	0.000379	0.000379	CcSEcCtD
Tobramycin—Nausea—Prednisone—chronic obstructive pulmonary disease	0.00036	0.00036	CcSEcCtD
